bevacizumab,panitumumab
roche,amgen,takeda
['crc,(-ccrcc),(-tbcrc049),(-mccrcc),(-mbcrc)', 'crcsm', 'paradigm']
paradigm continuing to support first line anti-egfr in first line left-sided ras/braf wt mcrc. hoping future trials select patients with better ngs analysis to insure we pick the correct patients. perhaps with better genomic selection sidedness will not matter? #asco23 #crcsm 
GI Oncologist at @IUCancerCenter. @uw_hemeoncpc and @UChicagomed alum. Tweets are my own.